Syngene International, an integrated research, development and manufacturing services company, announced the extension of its long-standing multi-discipline research collaboration with Amgen, a leading biotechnology company.

The contract is currently extended until the end of 2026 and its scope includes integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development.

In addition to operating the existing Syngene Amgen R&D Center (SARC), under the new contract, Syngene will also build and operate a dedicated laboratory.

SARC was established in 2016 and Syngene announced the expansion of the originally dedicated centre in 2017. It currently consists of 60,000 sq ft of floor space and a dedicated team of multi-disciplinary Syngene scientists who work closely with Amgen researchers around the world on the discovery and development of innovative medicines.